Indivior to Announce Year-to-Date and Q3 2024
Results and Host Webcast on October 24th
Slough, UK, and Richmond,
VA, October 15, 2024 -
Indivior PLC (NASDAQ/LSE: INDV) today announced
that it will release its year-to-date and Q3 2024 results on
October 24th at 7:00 a.m. London
time (2:00 a.m. U.S. Eastern). The results
will be available via the London Stock Exchange's Regulatory News
Service (RNS) and on the "Investors" section of the company's
website at www.indivior.com.
Mark Crossley, Chief Executive
Officer, and other members of Indivior's leadership team will host
a presentation via live webcast at 1:00 p.m. London time (8:00 a.m.
U.S. Eastern) on October 24th.
Access to the Live Webcast
Presentation:
The webcast event and materials can
be accessed on the "Investors" section of the company's website
at www.indivior.com before the event begins.
The webcast link:
https://edge.media-server.com/mmc/p/ppm4ske8
Participants may access the
presentation telephonically by registering with the following
link:
https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64
(Registrants will have an option to be called
back directly immediately prior to the call or be provided a
call-in # with a unique pin code following their
registration)
A replay of the presentation will be
available at www.indivior.com.
About Indivior
Indivior is a global pharmaceutical company working to
help change patients' lives by developing medicines to treat
substance use disorders (SUD), overdose and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs approximately 1,000 individuals globally and its portfolio
of products is available in over 30 countries worldwide. Visit
www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting
www.linkedin.com/ company/indivior.
Contact:
Jason Thompson
Vice President, Investor
Relations
Tel: 804-402-7123 or
jason.thompson@indivior.com
Tim Owens
Director, Investor
Relations
Tel: 804-263-3978 or
timothy.owens@indivior.com
###